financetom
Business
financetom
/
Business
/
BNP Paribas in talks to buy AXA Investment Managers for 5.1 billion euros
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BNP Paribas in talks to buy AXA Investment Managers for 5.1 billion euros
Aug 1, 2024 12:05 PM

PARIS (Reuters) - BNP Paribas is in exclusive talks with French insurer AXA to buy 100% of its AXA Investment Managers arm at an agreed price of 5.1 billion euros ($5.50 billion), the euro zone's biggest bank said on Thursday.

For BNP, such an acquisition would significantly boost its asset management arm as the industry is in a race for size to achieve economies of scale and lower costs.

This represents a major strategic move for AXA, Europe's second-biggest insurer, as it aims to focus on its core businesses - life insurance, savings, property and casualty policies as well as health insurance.

The would-be combined entity would have total assets under management of about 1.5 trillion euros, BNP said in a statement, and it would become one of the top European asset managers after leader Amundi, which had 2.16 trillion euros of assets under management at the end of June.

BNP said it expected the transaction to close in mid-2025. The bank said the acquisition will have an impact of about 25 basis points on its CET1 ratio -- a key measure of financial strength.

AXA said in a separate statement that BNP would pay 5.1 billion euros in cash.

AXA said it would receive 300 million euros in addition for the acquisition by AXA IM of Select, a company owned by AXA that offers investment solutions, such as management of funds.

The French insurer said it would use 3.8 billion euros' worth of proceeds from these sales in share buybacks. The rest of the proceeds will be spent on "organic and inorganic growth", AXA Deputy CEO Frederic de Courtois said in a call with reporters.

The transaction also includes a 15-year agreement under which BNP would provide investment management services to AXA.

($1 = 0.9276 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Jul 31, 2025
* Mounjaro reduces major heart problems by 8% versus Trulicity in trial * Death from any cause was 16% lower for patients on Mounjaro versus Trulicity * Safety profile similar for both drugs (Adds trial detail, paragraph 4, shares and analyst comment in paragraph 5, cardiologist comment, paragraph 6) By Patrick Wingrove July 31 (Reuters) - Eli Lilly ( LLY...
Stagwell Shares Rise After Q2 Adjusted EPS, Revenue Beat Estimates
Stagwell Shares Rise After Q2 Adjusted EPS, Revenue Beat Estimates
Jul 31, 2025
10:07 AM EDT, 07/31/2025 (MT Newswires) -- Stagwell ( STGW ) shares were rising 14% in recent Thursday trading after its Q2 adjusted EPS and revenue rose year on year and beat analysts' estimates. The company reported Q2 adjusted earnings Thursday of $0.17 per diluted share, up from $0.14 a year earlier. Analysts polled by FactSet expected $0.16. Revenue for...
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Jul 31, 2025
Sanofi SA reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion. Sales increased 6% year over year, up 10.1% in constant currency, driven by growth in Immunology, pharmaceutical launches and Beyfortus. The French drug maker reported that in the second quarter of 2025, business operating income reached € 2.46 billion, down 2.4% year over...
Copyright 2023-2026 - www.financetom.com All Rights Reserved